Immunocryosurgery for non-superficial basal cell carcinoma: A prospective, open-label phase III study for tumours ≤ 2 cm in diameter

Acta Dermato-Venereologica

Volumn 94, Issue 1, 2014, Pages 38-44

  Gaitanis, Georgios ^a   Bassukas, Ioannis D ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Basal cell carcinoma; Cryosurgery; Im munocryosurgery; Imiquimod

Indexed keywords

IMIQUIMOD; LIQUID NITROGEN;

ADULT; AEROSOL; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER THERAPY; CRYOSURGERY; EVENING DOSAGE; FEASIBILITY STUDY; FEMALE; HUMAN; IMMUNOCRYOSURGERY; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; COMBINED MODALITY THERAPY; CRYOSURGERY; FACIAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT FAILURE; TUMOR BURDEN;

EID: 84890184966     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1609     Document Type: Article

References (27)

1. Demers AA, Nugent Z, Mihalcioiu C, Wiseman MC, Kliewer E V. Trends of nonmelanoma skin cancer from 1960 through 2000 in a Canadian population. J Am Acad Dermatol 2005; 53: 320-328.
2. Richmond-Sinclair NM, Pandeya N, Ware RS, Neale RE, Williams GM, van der Pols JC, et al. Incidence of basal cell carcinoma multiplicity and detailed anatomic distribution: longitudinal study of an Australian population. J Invest Dermatol 2009; 129: 323-328.
3. Dyer RK, Weinstock MA, Cohen TS, Rizzo AE, Bingham SF. Predictors of basal cell carcinoma in high-risk patients in the VATTC (VA Topical Tretinoin Chemoprevention) trial. J Invest Dermatol 2012; 132: 2544-2551.
4. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135: 1177-1183.
5. Smeets NW, krekels GA, Ostertag JU, Essers BA, Dirk-sen CD, Nieman FH, et al. Surgical excision vs Mohs micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 2004; 364: 1766-1772.
6. Tucker SB, Polasek JW, Perri AJ, Goldsmith EA. Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. J Am Acad Dermatol 2006; 54: 1033-1038.
7. Eigentler TK, kamin A, Weide BM, Breuninger H, Caroli UM, Möhrle M, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol 2007; 57: 616-621.
8. Shumack S, Robinson J, kossard S, Golitz L, Greenway H, Schroeter A, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002; 138: 1165-1171.
9. O'Bryan kW, Ratner D. The role of targeted molecular inhibitors in the management of advanced nonmelanoma skin cancer. Semin Cutan Med Surg 2011; 30: 57-61.
10. Kasper M, Jaks V, Hohl D, Toftgard R. Basal cell carcinoma - molecular biology and potential new therapies. J Clin Invest 2012; 122: 455-463.
11. Gaitanis G, Nomikos K, Vava E, Alexopoulos EC, Bassukas ID. Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application. J Eur Acad Dermatol Venereol 2009; 23: 1427-1431.
12. Gaitanis G, Nomikos K, Vlachos C, Bassukas ID. Immu-nocryosurgery for patients with therapeutically challenging basal cell carcinomas: report of two representative cases. J Dermatolog Treat 2012; 23: 70-71.
13. Gaitanis G, kalogeropoulos C, Bassukas ID. Imiquimod can be combined with cryosurgery (immunocryosurgery) for locally advanced periocular basal cell carcinomas. Br J Ophthalmol 2011; 95: 890-892.
14. Jebodhsingh KN, Calafati J, Farrokhyar F, Harvey JT. Recurrence rates of basal cell carcinoma of the periocular skin: what to do with patients who have positive margins after resection. Can J Ophthalmol 2012; 47: 181-184.
15. Bassukas ID, Gaitanis G. Combination of cryosurgery and topical imiquimod: does timing matter for successful im-munocryosurgery? Cryobiology 2009; 59: 116-117.
16. Gaitanis G, Alexopoulos EC, Bassukas ID. Cryosurgery is more effective in the treatment of primary, non-superficial basal cell carcinomas when applied during and not prior to a fve week imiquimod course: a randomized, prospective, open-label study. Eur J Dermatol 2011; 21: 952-958.
17. Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 2006; 19: S127-147.
18. Yoon HS, Choi JW, Youn JI. Method of assessing involved facial areas: rule of fours. Br J Dermatol 2008; 158: 1022-1028.
19. van der Geer S, Martens J, van Roij J, Brand E, Ostertag JU, Verhaegh ME, et al. Imiquimod 5% cream as pretreat-ment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study. Br J Dermatol 2012; 167: 110-115.
20. Heal CF, Buettner PG, Drobetz H. Risk factors for surgical site infection after dermatological surgery. Int J Dermatol 2012; 51: 796-803.
21. Butler DF, Parekh PK, Lenis A. Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular nasal basal cell carcinomas before Mohs micrographic surgery: a randomized, double blind, vehicle-controlled study. Dermatol Surg 2009; 35: 24-29.
22. van der Geer S, Frunt M, Romero HL, Dellaert NP, Jansen-Vullers MH, Demeyere TB, et al. One-stop-shop treatment for basal cell carcinoma, part of a new disease management strategy. J Eur Acad Dermatol Venereol 2012; 26: 1154-1157.
23. Stern RS. Prevalence of a history of skin cancer in 2007: results of an incidence-based model. Arch Dermatol 2010; 146: 279-282.
24. Christensen E, Mork C, Skogvoll E. High and sustained efficacy after two sessions of topical 5-aminolaevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10-year follow-up study. Br J Dermatol 2012; 166: 1342-1348.
25. Osiecka B, Jurczyszyn K, Ziolkowski P. The application of Levulan(R)-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma. Med Sci Monit 2012; 18: PI5-9.
26. MacFarlane DF, El Tal AK. Cryoimmunotherapy: superficial basal cell cancer and squamous cell carcinoma in situ treated with liquid nitrogen followed by imiquimod. Arch Dermatol 2011; 147: 1326-1327.
27. Messeguer F, Serra-Guillen C, Echeverria B, Requena C, Sanmartin O, Llombart B, et al. A pilot study of clinical efficacy of imiquimod and cryotherapy for the treatment of basal cell carcinoma with incomplete response to imiqui-mod. J Eur Acad Dermatol Venereol 2012; 26: 879-881.